The Recall Desk
HighFDA (Drugs)·D-0244-2026·Announced 2026-01-07

Novo Nordisk Recalls Wegovy Semaglutide Injection Pens for Hair Contamination

Novo Nordisk is recalling specific Wegovy (semaglutide) injection pens because hair was found in prefilled syringes. The recall affects certain lots distributed nationwide.

What this means for you

Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.

Our severity reasoning: FDA Class II drug recall with particulate matter (hair) contamination in an injectable product and no reported illnesses or injuries. This represents a risk-of-harm product where injury has not yet been reported, consistent with the rubric criterion for High severity.

Plain-English summary

Novo Nordisk Inc. is recalling specific lots of Wegovy (semaglutide) Injection, 0.5 mg/0.5 mL, 4 Single-Dose Prefilled Pens due to the presence of hair in prefilled syringes.

The affected lots are RZFHD52 and RZFHW93, with an expiration date of 10/31/2026. These products were distributed nationwide within the United States. Hair found in a prefilled syringe could potentially compromise the integrity of the injection and pose a risk if administered to patients.

Patients who have received or are using affected pens should contact their healthcare provider or Novo Nordisk if they believe they have one of the recalled pens. Healthcare providers and pharmacies should cease dispensing affected lots immediately and follow FDA and Novo Nordisk guidance on return and disposal of recalled product.

The recalled product

Product
WEGOVY (SEMAGLUTIDE)
Brand
WEGOVY
Manufacturer
Novo Nordisk Inc.
Hazard
  • hair-contamination
  • foreign-object
  • contamination

Is your product affected?

Check your packaging against the codes below. If any of them match, the product is part of this recall.

Lot numbers (3)

  • Lot #: RZFHD52
  • RZFHW93
  • Exp Date 10/31/2026

Distribution

Distributed nationwide across the United States.

Same brand · WEGOVY